Top 50 Biotechnology Startup Investors in Israel (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Trendlines Group
VC Fund
|
20 | Israel, Singapore, United Kingdom | Seed, Series A | Health Care, Biotechnology, Medical Device | $650k–$15M |
|
Pontifax
VC Fund
|
16 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $6.3M–$130M |
|
Israel Innovation Authority
VC Fund
|
15 | Israel, United States, Mali | Grant, Seed, Pre-Seed | Health Care, Artificial Intelligence, Biotechnology | $130k–$5M |
|
OurCrowd
VC Fund
|
13 | Israel, United States, New Zealand | Series B, Series A, Seed | Software, Artificial Intelligence, Health Care | $593k–$65M |
|
OrbiMed
VC Fund
|
9 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$183M |
|
aMoon Fund
VC Fund
|
8 | United States, Israel, France | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5.7M–$93M |
|
Welltech Ventures
VC Fund
|
7 | Israel, United States, Poland | Seed, Series A | Health Care, Artificial Intelligence, mHealth | $718k–$20M |
|
ZORA Ventures
VC Fund
|
7 | Israel, United States, United Kingdom | Seed, Series A, Convertible Note | Biotechnology, Health Care, Food and Beverage | $1M–$8.6M |
|
Arkin Holdings
VC Fund
|
6 | Israel, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2M–$95M |
|
Docor International Management
VC Fund
|
6 | Israel, United States | Series C, Series A | Health Care, Biotechnology, 3D Technology | $13M–$22M |
|
HBL Hadasit Bio Holdings
VC Fund
|
6 | Israel | Seed, Series A | Biotechnology, Medical, Health Care | |
|
S2G Investments
VC Fund
|
6 | United States, Canada, Israel | Series A, Series B, Series C | Food and Beverage, Agriculture, Biotechnology | $3.9M–$100M |
|
Clal Biotechnology Industries
VC Fund
|
5 | Israel, United States | Series A, Series B | Health Care, Biotechnology, Medical Device | $4M–$55M |
|
Consensus Business Group
VC Fund
|
5 | Israel, United States, United Kingdom | Seed, Series A | Health Care, Medical Device, Medical | $1M–$10M |
|
Siddhi Capital
VC Fund
|
5 | United States, Israel, Canada | Seed, Series A, Pre-Seed | Food and Beverage, Biotechnology, AgTech | $1M–$21M |
|
Milk & Honey Ventures
VC Fund
|
5 | Israel | Pre-Seed, Seed, Series A | Food and Beverage, Biotechnology, Nutrition | $1M–$5.2M |
|
iAngels
VC Fund
|
5 | United States, Israel, United Kingdom | Seed, Series A | Artificial Intelligence, Software, Financial Services | $900k–$22M |
|
Tnuva
VC Fund
|
4 | Israel | Seed, Series A, Series B | Biotechnology, Food and Beverage, Food Processing | $1.2M–$6M |
|
Cancer Focus Fund
VC Fund
|
4 | Israel, United States, Germany | Venture - Series Unknown, Series A, Seed | Biotechnology, Medical, Health Care | $4.5M–$47M |
|
fresh.fund
VC Fund
|
4 | Israel, United States, Norway | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $300k–$21M |
|
Johnson & Johnson Robotics and Digital Solutions
VC Fund
|
4 | United States, Israel, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $300k–$100M |
|
ALIVE Israel HealthTech Fund
VC Fund
|
4 | Israel, United States | Series A, Series C, Series B | Health Care, Medical, Medical Device | $4.4M–$55M |
|
Takeda Ventures
VC Fund
|
4 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
Grove Ventures
VC Fund
|
4 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $3.5M–$74M |
|
New York Ventures
VC Fund
|
4 | United States, Canada, Israel | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.5M–$53M |
|
GlenRock Israel
VC Fund
|
4 | Israel, United States | Seed, Series A, Series B | Software, Health Care, Cyber Security | $100k–$30M |
|
FutuRx
VC Fund
|
4 | Israel | Seed | Biotechnology, Life Science, Biopharma | |
|
Millenium Food-Tech
VC Fund
|
4 | Israel | Seed, Series A, Series B | Food and Beverage, Manufacturing, Retail | $2.5M–$105M |
|
Integra Holdings
VC Fund
|
4 | Israel | Seed, Series B, Series F | Biotechnology, Pharmaceutical, Life Science | |
|
Sapir Venture Partners
VC Fund
|
4 | Israel, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Biotechnology, Analytics | $1.3M–$40M |
|
Tal Ventures
VC Fund
|
3 | Israel, United States, Cyprus | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, SaaS | $2.1M–$25M |
|
Yossi Ackerman
Angel
|
3 | Israel, United States | Seed, Angel, Series A | Apps, Local, Mobile | |
|
DSM Venturing
VC Fund
|
3 | United States, Canada, Israel | Series A, Series B | Health Care, Biotechnology, Manufacturing | $3.5M–$32M |
|
Ziegler Meditech Equity Partners
VC Fund
|
3 | United States, Israel | Series C, Series E, Series F | Health Care, Biotechnology, Mobile | |
|
HackCapital
VC Fund
|
3 | United States, Israel, United Kingdom | Seed, Pre-Seed, Series A | Food and Beverage, Biotechnology, Food Processing | $500k–$12M |
|
SciSparc
VC Fund
|
3 | Israel | Corporate Round | Pharmaceutical, Cannabis, Biopharma | $400k–$700k |
|
Tempo Beverages Cyprus Ltd.
VC Fund
|
3 | Israel | Venture - Series Unknown, Series A | Biotechnology, AgTech, Nutrition | $1.5M–$9M |
|
Accelmed
VC Fund
|
3 | United States, Israel | Series D, Series A | Health Care, Medical Device, Medical | $695k–$96M |
|
Nevateam Partners
VC Fund
|
3 | Israel | Seed, Series A | AgTech, SaaS, Farming | $5M–$10M |
|
Pitango VC
VC Fund
|
3 | Israel, United States, China | Series B, Series A, Series C | Software, Health Care, Information Technology | $4M–$100M |
|
CPT Capital
VC Fund
|
3 | United States, Israel, United Kingdom | Seed, Series A, Series B | Food and Beverage, Biotechnology, Food Processing | $1.3M–$226M |
|
RMGP Biopharma Investment Fund
VC Fund
|
3 | Israel | Seed, Series B | Biotechnology, Biopharma, Life Science | |
|
Italian Angels for Growth
VC Fund
|
3 | Italy, United States, United Kingdom | Seed, Angel, Series A | Software, E-Commerce, Health Care | $219k–$14M |
|
PeakBridge
VC Fund
|
3 | Israel, United States, United Kingdom | Series A, Seed, Series B | Food and Beverage, Health Care, Food Processing | $501k–$50M |
|
Agriline
VC Fund
|
3 | Israel | Seed, Series A, Venture - Series Unknown | Health Care, Medical, Medical Device | $1.3M–$17M |
|
Neo Ventures
VC Fund
|
3 | United States, United Kingdom, Israel | Seed, Series A | Software, Artificial Intelligence, SaaS | $500k–$24M |
|
South Israel Bridging Fund
VC Fund
|
3 | Israel, Cyprus, United States | Series A, Venture - Series Unknown, Series B | Software, Biotechnology, Energy | $750k–$34M |
|
Israel Biotech Fund
VC Fund
|
3 | Israel, United States | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$45M |
|
Office of the Chief Scientist
VC Fund
|
3 | Israel | Seed | Health Care, Biotechnology, Hardware | $500k–$1M |
|
EIT Food
VC Fund
|
3 | United Kingdom, Israel, Germany | Grant, Non-Equity Assistance, Seed | Biotechnology, Food and Beverage, Food Processing | $1.2k–$9.7M |
| Access all 745 investors in Israel Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Israel, Singapore, United Kingdom
Investor stats
- Total investments: 70
- Round size: Seed $650k–$4.1M; Series A $2.3M–$15M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- IBI-Ag — We develop a wide array of selective bio-insecticides to help farmers grow more at lower cost with no harm to farm workers, consumers and the environment.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 117
- Round size: Series A $6.3M–$110M; Series B $20M–$130M; Series C $12M–$101M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- ArQule — ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
- Otic Pharma — Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing anasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Grant, Seed, Pre-Seed
- Geography: Israel, United States, Mali
Investor stats
- Total investments: 200
- Round size: Seed $500k–$5M; Grant $130k–$3.5M; Pre-Seed $150k–$2.1M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Brevel — Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed.
- NanoGhosts — NanoGhosts’ technology is based on its founder’s research, that the Technion's commercial unit has patented in the U.S. and Europe.
- GeoRank Studio — Get your business ranked on Google, cited by ChatGPT & Perplexity, and protected from reputation damage. Specialist SEO and GEO agency. Free consultation.
Invest in exclusive and pre-vetted startups, late-stage companies, and top tier funds - private market access made simple, transparent, and institutional-grade.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series B, Series A, Seed
- Geography: Israel, United States, New Zealand
Investor stats
- Total investments: 309
- Round size: Seed $593k–$10M; Series A $5.3M–$34M; Series B $8M–$65M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- N.Light — N.Light is a Metaverse 3D design software that allows individuals to effortlessly turn their ideas into reality.
- Hemispheric — Hemispheric develops fundamental AI technologies aimed at deciphering brain activity for innovative applications.
- MUV Interactive — MUV Interactive designs and develops innovative technology for active human sensing, providing a natural and fluent interactive experience with any type of digital application, from displayed content, and smart home appliances to IOT (Internet of Things) devices, drones and AR/VR applications. The company’s flagship product, Bird, is anintuitive device that is worn on the index finger, which transforms any space into a 3D Interactive Environment. Bird is the first device to integrate the entire spectrum of input and control methods – including touch, remote touch, gesture control and mouse functionality. This gives users the flexibility to interact with each type of digital content in the most intuitive way, whether up close or from a distance of up to 100 feet away.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 653
- Round size: Series A $10M–$150M; Series B $24M–$150M; Series C $18M–$183M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- CardiAQ Valve Technologies — CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Acceleron Pharma — At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 79
- Round size: Series A $5.7M–$82M; Series B $22M–$93M; Series C $30M–$82M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Lin Health — Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction results.
- Connie Health — At Connie Health, our Medicare advisors help older Americans find the right Medicare plan - all at no cost to you.
Welltech Ventures is Israel’s leading fund focused exclusively on investing in the health and wellness space. We seek to partner with entrepreneurs who epitomize the Startup Nation’s ethos and are building paradigm-shattering companies that are making an impact in the wellness space. As thought leaders we work with global investors focused onaccessing and investing in the Israeli tech ecosystem’s most promising entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, mHealth
- Stage:Seed, Series A
- Geography: Israel, United States, Poland
Investor stats
- Total investments: 23
- Round size: Seed $718k–$19M; Series A $6M–$20M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- MDI Health — Transform Quality Metrics Clinical Outcomes & Costs all inOne Platform. Your AI Co-Pilot for Medication Management
- Antidote Health — AntidoteHealth.ai offers primary care on its telehealth app on a 24/7 basis, including prescriptions & more. Book your appointment today!
- Marquee — Marquee turns football data into decision-ready insights in seconds, unifying external and internal data and filtering it through your club's sporting DNA.
Impact investing in Israeli technology. ZORA is an impact investing fund investing in early-stage Israeli companies solving global challenges in health, education, economic inclusion and the environment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Food and Beverage
- Stage:Seed, Series A, Convertible Note
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 16
- Round size: Seed $1M–$8.6M; Series A $4M–$8.1M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Newmoo — Newmoo makes plant-based cheeses and dairy alternatives.
- WeedOut — WeedOut: Exploiting Sterility against Resistant Weeds
- Earth Force Technologies — Earth Force is a Vegetation Management System platform.
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: Israel, United States, Switzerland
Investor stats
- Total investments: 31
- Round size: Seed $2M–$6M; Series A $15M–$29M; Series B $23M–$95M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $270M in 2021
Portfolio highlights
- Lendbuzz — Lendbuzz is an AI-based auto finance platform that helps consumers with thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by the traditional banks. By partneringwith auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. Lendbuzz is headquartered in Boston, Massachusetts and was founded in 2015.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.
Docor International B.V. is a fully-owned subsidiary of Crecor B.V. Both Docor and Crecor were formed as wholly-owned subsidiaries of the Van Leer Group Foundation to promote and participate in commercial activities in Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, 3D Technology
- Stage:Series C, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 14
- Round size: Series C $13M–$22M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Check-Cap — Check-Cap Ltd. is merging with MBody AI to create a leading publicly traded embodied AI company powering autonomous workforces.
- Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
- Raziel Health — Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 11
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.
S2G Ventures is is a multi-stage venture fund investing in food and agriculture. We're harnessing the power of food innovation to create better outcomes for people and the planet.
Show more...Investment focus
- Industry: Food and Beverage, Agriculture, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 215
- Round size: Series A $4M–$50M; Series B $3.9M–$100M; Series C $9.4M–$92M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Atomo Coffee — Atomo Coffee is a developer of molecular coffee. Atomo has reverse-engineered the coffee bean to create a smooth cup of coffee, made of naturally derived ingredients, and more sustainable than current commercial coffee.
- SWARM — SWARM is a Software-as-a-Service platform that uses a next generation cognitive computing system, structured around a multi-agent approach which can utilize a cur
- Kuehnle Agrosystems — Kuehnle AgroSystems curates a unique set of algae originating from pristine waters and ecosystems of Hawaii, as well as tropical botanical accessions representing plants prized by Polynesian voyagers.
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 15
- Round size: Series A $4M–$55M; Series B $15M–$33M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- TytoCare — TytoCare offers the Home Smart Clinic - for accessible, high-quality primary care from home, with no compromises.
- Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
- Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Acting as advisor to companies within the Tchenguiz Family Trust, Consensus Business Group has amassed a portfolio of over 300,000 residential freeholds worth over £4 billion and a commercial portfolio worth over £2 billion.Consensus Business Group has vast experience and a proven track record of acquiring stock directly from nationalhousebuilders and developers over 20 years.As a result of their strategic investment, Consensus Business Group is believed to be the largest owner and asset manager of residential freehold interests in the UK, representing in excess of 1% of the housing stock in England and 1.2% in Greater London.Their decisions are not subject to procrastinated board approval or credit committees and as a result they are able to perform quickly and consistently. They are not dependent on debt finance and they have immediate cash availability.Consensus Business Group prides itself on having the market knowledge and expertise to stand out from its competitors, and it is their diligent and efficient acquisition practices that ensure swift transactions.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 23
- Round size: Seed $1.3M–$4.5M; Series A $1M–$10M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- IBI-Ag — We develop a wide array of selective bio-insecticides to help farmers grow more at lower cost with no harm to farm workers, consumers and the environment.
- Synchrony Medical — Synchrony Medical is a clinical stage medical device company developing LibAirty, a next generation, home-use, airway clearance system designed to help patients with chronic lung disease such as COPD and CF maintain clear lungs with a short, daily, proficient treatment.
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
Siddhi Capital is the growth equity partner for convention-crushing food and beverage companies.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, AgTech
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 59
- Round size: Seed $1.7M–$6.3M; Pre-Seed $1M–$3.6M; Series A $5M–$21M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Nopalera — Vegan, cruelty free, and Latina owned. Handmade cactus products that celebrate culture and resilience.
- Pigmentum — Pigmentum is an ag-tech firm developing a molecular technology platform that enables external gene activation in plants.
- ProFuse Technology — ProFuse Technology revolutionizes cultured meat production by shortening it duration, improving the meat quality and increasing yields.
Tel-Aviv based investment firm, focused on the effective acceleration of disruptive New Protein technologies
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Nutrition
- Stage:Pre-Seed, Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 6
- Round size: Seed $3.5M–$5.2M; Pre-Seed $1M–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
- SuperMeat — SuperMeat is an Israeli bio-tech and food-tech company, developing a technology to create clean meat from chicken cells in a safe and controlled environment, external to the animal’s body. SuperMeat is set to revolutionize the meat industry from its core, aspiring to secure a better future for humans and animals alike. Clean meat is grown in acontrolled, sterile environment without the use of antibiotics and without any possibility of fecal contamination, such as salmonella. Clean meat will require significantly less resources for its production (99% less land, 90% less water), making it both a healthy and sustainable food source for the coming century.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
iAngels is a VC and angel investment platform that leverages due diligence and analytics to enable accredited investors around the world the ability to invest in early-stage technology deals in Israel.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Financial Services
- Stage:Seed, Series A
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 133
- Round size: Seed $900k–$10M; Series A $4.5M–$22M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $56M in 2021
Portfolio highlights
- Nas Daily —
- ActiveLens — Full automation. Full visibility. Always in control.
- Recapp — Recapp Sports Highlights is a video-format app for NBA, NFL, CBB, WNBA, MLB, NHL, CFB, and MLS game recaps, news, and highlights in one app
On the Tnuva website you will find information about the Company, its subsidiaries, press releases, the Program for Better Nutrition, contacting customer service and more.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Seed, Series A, Series B
- Geography: Israel
Investor stats
- Total investments: 6
- Round size: Seed $1.2M–$6M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Pigmentum — Pigmentum is an ag-tech firm developing a molecular technology platform that enables external gene activation in plants.
- Ever After Foods — We produce slaughter-free meats that prevent animal cruelty, and support health, security and sustainability for our planet and its people.
- ProFuse Technology — ProFuse Technology revolutionizes cultured meat production by shortening it duration, improving the meat quality and increasing yields.
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: Israel, United States, Germany
Investor stats
- Total investments: 10
- Round size: Series A $5.4M–$28M; Venture - Series Unknown $4.5M–$47M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.
fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, Norway
Investor stats
- Total investments: 44
- Round size: Seed $1.6M–$10M; Pre-Seed $300k–$6M; Series A $11M–$21M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Kimba — Kimba is the first sleep system that reads your body and responds to it silently and automatically every night, using the only sensory pathway that can reach a sleeping brain. Reserve your Kimba today!
- CopilotKit — The Enterprise-Ready Frontend Stack for Agents. CopilotKit lets you integrate LLMs or agents with real-time context, UI control, and full flexibility.
- Shifters AI — Shifters builds autonomous robotic teams for dangerous ground missions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Healthcare innovation wherever it originates.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 77
- Round size: Series A $5.9M–$63M; Series B $18M–$55M; Series C $300k–$100M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
- Manus Neurodynamica — Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.
- Glyphic Biotechnologies — We sequence proteins. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolution to enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of life itself.
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series C, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 15
- Round size: Series A $4.4M–$17M; Series B $22M–$30M; Series C $30M–$55M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Navina — Navina uses medically-informed AI to replace disorganized patient data with an intuitive Patient Portrait - a logical grid that makes it possible for every primary care physician to assess even the most complex cases in minutes. Designed for and loved by physicians, Navina allows for high quality and empathic patient care, resulting in better treatment, reduced missed diagnoses and enhanced financial performance for providers and payers.
- Vessi Medical — Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
- Magenta Medical — Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Grove Ventures is a leading early-stage venture capital fund in Israel. It partners with seed and early-stage founders
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 73
- Round size: Seed $3.5M–$20M; Series A $8M–$50M; Series B $20M–$74M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- LimitlessCNC — Limitless CNC is an AI-powered technology intended to improve CNC machining operations. It offers an AI CAM agent that works with NX-CAM to give industry-specific strategies and operations.
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
- FormX — California's trusted sustainable builders. FormX delivers fully customized single-family homes, ADUs, and backyard offices built faster with component-based modular construction.
New York Ventures is dedicated to encouraging innovation and fueling economic growth in communities across the State. This venture capital investment arm of Empire State Development is one of New York State's business resources and innovation investments, including the Governor's START-UP NY program, Innovation Hot Spots, the RegionalEconomic Development Councils, the Centers of Advanced Technology and Centers of Excellence networks, and the SUNY 2020 Initiative.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 132
- Round size: Seed $1.5M–$7M; Series A $3M–$20M; Series B $2.5M–$53M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Adro — Designed to work when you arrive Spend and save like a local. Easy to use. No unfair fees.
- BQP — At BQP, we’re developing a quantum-accelerated digital twin platform for mission-critical applications. The platform, BQPhy, is a back-end engine that integrates seamlessly into existing engineering workflows and operates on today’s infrastructure without requiring quantum hardware. BQPhy helps teams solve large-scale, complex challenges inengineering optimization, data-driven modeling (ML), and physics-based (CFD) simulations. We are bridging the gap between current high-performance computers and future quantum systems with probabilistic algorithms from quantum information science, unlocking simulation capabilities that were previously impractical or impossible. BQPhy reduces time, accuracy, and throughput inefficiencies, thereby accelerating development cycles, unlocking previously unexplored design spaces, lowering costs, and enhancing product outcomes.
- CryoBio — CryoBio offers a food-safe spray solution to protect crops from extreme frost, reducing losses and replacing manual labor with effective, biodegradable frost protection technology.
A Private Equity Investment Company Founded by Leon Recanati in 2003, GlenRock leverages a unique combination of private equity, multidisciplinary in-house expertise, unmatched access to quality dealflow, and a focused but flexible investment strategy to achieve maximum returns.
Show more...Investment focus
- Industry: Software, Health Care, Cyber Security
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 35
- Round size: Seed $1M–$9M; Series A $1.5M–$9M; Series B $100k–$30M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Treetoscope — The first and only commercial device that senses the internal water flow of a plant and directly measures its water consumption and real-time irrigation needs. without extrapolations based on indirect sensing technologies.Treetoscope offers a SaaS irrigation management platform, based on direct plant sensing technology. We tackle one of the mostcrucial challenges farmers face today: water scarcity and irrigation optimization. Our groundbreaking ag-tech enables the unprecedented measurement of real-time actual water use of trees (based on our patented single probe Sap Flow sensor). Through the Treetoscope solution, growers gain great value as a result of the affordability, scalability, and ease of deployment of our technology.
- MSICS Pharma — MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for medical purpose.
- Quris — Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel.
FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Biopharma
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skip Therapeutics — Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
- Bsense Bio Therapeutics — Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.
Millennium Food-Tech is an R&D partnership traded on the Tel Aviv Stock Exchange that specializes in investment in and betterment of companies in food-tech sectors,. Millennium seeks to invest in companies that specialize in identifying and developing innovative, and transformative ideas in the food, drinks, and nutrition industry. Millenniumhas experienced management, proven solutions, and a supportive network to develop ideas and start-ups from early-stage to maturity to exit.
Show more...Investment focus
- Industry: Food and Beverage, Manufacturing, Retail
- Stage:Seed, Series A, Series B
- Geography: Israel
Investor stats
- Total investments: 19
- Round size: Seed $2.5M–$6M; Series A $3.5M–$15M; Series B $17M–$105M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- TripleW Group NV — Making Waste History. TripleW upcycles food waste into high-value bioplastic
- ansā — Ansā is a coffee roasting solution designed specifically for the workplace. It offers a system that enables organizations to roast coffee on-site. The solution focuses on providing fresh coffee tailored to workplace preferences. The industries served include food service and hospitality.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Life Science
- Stage:Seed, Series B, Series F
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
- Splisense — Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs), restore and modify protein functionality, addressing untreatable pulmonary diseases.
- Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria
Early Stage VC
Show more...Investment focus
- Industry: Software, Biotechnology, Analytics
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 21
- Round size: Seed $1.3M–$10M; Series A $10M–$40M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
- Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
- DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!TAL Ventures (TAL) is an Israel based Venture Capital group with deep ties to the Israel high-tech ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: Israel, United States, Cyprus
Investor stats
- Total investments: 59
- Round size: Seed $3M–$12M; Pre-Seed $2.1M–$4M; Series A $5M–$25M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- TULU — TULU is a smart platform and amenity services provider to over 10,000 people in 50 buildings across the United States, Europe and Israel. Founded in 2019, TULU provides urban tenants with on-demand access to hundreds of brand name appliances, grocery staples, micro-mobility and entertainment devices, and more. TULU’s IoT-based modular units arecustomized to provide the most necessary and useful items, while leveraging advanced machine learning tools to analyze behavioral patterns, optimize usage, refine inventory, and create a personalized experience for our users. The outcome is a new way of living, encouraging more responsible consumption, reducing the cost of living in the city, and consistent with the trend to smaller and smaller living spaces.
- Yuki — Reduce warehouse waste, prevent budget spikes, and keep queries fast across Snowflake and BigQuery. Yuki keeps AI workloads under control with budgets and priorities built in, optimizing in real time with zero engineer effort.
- Majestic Labs ai — Majestic Labs ai builds power-efficient AI servers for the largest and most advanced AI workloads.
Joseph Ackerman, also known as Yossi, served as the Chief Executive Officer and President of Elbit Systems Ltd., the holding company of Elbit Security Systems Ltd. and Harpia Sistemas S.A. from 1996 to March 31, 2013. From 1994 to 1996, Joseph Ackerman served as Senior Vice President and General Manager of Elbit Ltd.'s Defense Systems Division(EDS.). He joined Elbit Ltd. in 1982 and held various management positions, including General Manager of EFW, Senior Vice President of Operations Group, Vice President of Operations and Vice President of Advanced Battlefield Systems. He serves as the Chairman of MediGuide Ltd. He served as the Chairman of Elbit Systems EW and SIGINT - Elisra Ltd. and Elbit Systems Ltd. He served as the Chairman of Tadiran Communications Ltd. since August 2005. He served as the Chairman of Elbit Systems Ltd. from 1996 to 2004. He served as the Vice Chairman of Elbit Systems Ltd. from April 1, 2013 to November 19, 2013. He serves as a Director of Imagesat International N.v. He served as a Director of Elbit Systems Ltd., the holding company of Elbit Systems EW and SIGINT - Elisra Ltd. from 1996 to 2004. Joseph Ackerman holds a Bachelor of Science degree in Aeronautical Engineering from the Israel Institute of Technology (the Technion).
Show more...Investment focus
- Industry: Apps, Local, Mobile
- Stage:Seed, Angel, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 7
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Musketeer — Help anywhere, anytime. Musketeer enables personal safety, alerting people close by and emergency services that someone needs help. In addition, it builds real life communities and promotes proactive safety by allowing people to ask for assistance, such as having someone walk them to their car because it's night and they don't want to bealone. All for free.Musketeer is the first social network dedicated to personal safety. By leveraging 21st century technology (crowdsourcing, cloud, and mobile) Musketeer enables users to seek assistance from people around them in case of distress. The system also provides safety related information in real-time and in aggregate for smarter Region/City management.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 94
- Round size: Series A $3.5M–$32M; Series B $5.6M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
Ziegler is a privately held investment bank, capital markets and proprietary investments firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Mobile
- Stage:Series C, Series E, Series F
- Geography: United States, Israel
Investor stats
- Total investments: 6
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Aposense — Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel.
- MAKO Surgical — MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
- MobileAccess Networks — Corning Everon Network Solutions offer in-building cellular solutions to meet a broad array of design scenarios and mitigate RF propagation challenges.
Join FoodTech focused investors looking to back impact-driven founders shaping our food system
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Food Processing
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 28
- Round size: Seed $1.9M–$12M; Pre-Seed $500k–$2.3M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- twig bio — twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients.
- Cosaic — Cultivated - Creamy, dairy-free indulgence
- UNCAGED Innovations — What if we could make leather without the animal? We are a biomaterials company combining the power of nature and technology to reimagine leather.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based ontetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.
Show more...Investment focus
- Industry: Pharmaceutical, Cannabis, Biopharma
- Stage:Corporate Round
- Geography: Israel
Investor stats
- Total investments: 4
- Round size: Corporate Round $400k–$700k
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- LaraPharm — LaraPharm Ltd. is a group of people joined together by the belief that active components found in the Cannabis plant can provide a real answer to hundreds of types of disease currently not addressed at all, or poorly addressed.
- AutoMax Motors — AutoMax Motors is a vehicle importer company. It involved in the parallel importation and selling of various private automobile products.
- MitoCareX Bio — MitoCareX Bio is a biotechnology company that focuses on the discovery and development of drugs for cancers & other life-threatening diseases.
Tempo Beverages Cyprus Ltd. is a producer and distributor of alcoholic and non-alcoholic beverages and the leading wine grower and wine producer in Israel. Tempo Beverages Cyprus Ltd is a subsidiary company of Tempo Israel, which is partially owned by Heineken NV Group.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Nutrition
- Stage:Venture - Series Unknown, Series A
- Geography: Israel
Investor stats
- Total investments: 3
- Round size: Venture - Series Unknown $1.5M–$9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Remilk — Remilk is a food-tech company that uses microbes to produce the key ingredients in milk. The company is developing technology for creating a milk substitute that is similar to cow milk in flavor, nutritional composition, composition, and functionality. It was founded in 2019 and is based in Tel Aviv, Israel.
- Pigmentum — Pigmentum is an ag-tech firm developing a molecular technology platform that enables external gene activation in plants.
- ProFuse Technology — ProFuse Technology revolutionizes cultured meat production by shortening it duration, improving the meat quality and increasing yields.
Accelmed is a venture capital firm that funds private and public medical device companies with significant market potential and proven clinical data.Concentrating on medical device companies that have already reached the revenue stage enables the firm to assist companies in benefiting from its managerial capabilities and financial resources.Together with the management teams of their portfolio companies, the Accelmed can steer the way from the clinical-stage to a profitable business with a clear commercial plan, thereby accelerating the path to a successful exit.In 2009, Mori Arkin and Uri Geiger, the co-founders of Accelmed, established the firm in Herzliya, Tel Aviv.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series D, Series A
- Geography: United States, Israel
Investor stats
- Total investments: 41
- Round size: Series A $695k–$24M; Series D $13M–$96M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Corvia Medical — Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts.
- UltraClear — UltraClear is a skincare clinic that provides facial rejuvenation solutions for the treatment of all skin types.
- GT Medical Technologies — GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement.
NevaTeam Partners is an Agri-Food Tech ESG Impact driven Fund with world-class knowledge and expertise that specializes in identifying and investing in cutting-edge companies and technologies, contributing to the streamlining and increase in world food production in a sustainable way.
Show more...Investment focus
- Industry: AgTech, SaaS, Farming
- Stage:Seed, Series A
- Geography: Israel
Investor stats
- Total investments: 5
- Round size: Seed $5M–$10M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Brevel — Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed.
- Clarifruit — First automated fruit and vegetable fresh produce quality control software solution by Clarifresh. Optimize your fresh produce QC >>
- Edete Precision Technologies for Agriculture — edete Precision Agriculture Technologies is solving the world’s ever-growing pollination challenge by developing and manufacturing an efficient, automated fruit orchard pollination system and providing optimized pollination services to companies and growers.By reducing the dependency on haphazard, insect-based pollination processes, edete’scontrolled and manageable mechanical pollination system improves the quantity and quality of fruit orchard yields.
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series B, Series A, Series C
- Geography: Israel, United States, China
Investor stats
- Total investments: 301
- Round size: Series A $4M–$50M; Series B $8.1M–$55M; Series C $8.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $175M in 2023
Portfolio highlights
- Convizit — Convizit's AI automatically captures user actions, adds properties, and delivers this behavioral data directly into your analytics and marketing platforms.
- Connie Health — At Connie Health, our Medicare advisors help older Americans find the right Medicare plan - all at no cost to you.
- QuantHealth — QuantHealth is an AI company that provides a platform to simulate clinical trials in order to accelerate and de-risk drug development.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Food Processing
- Stage:Seed, Series A, Series B
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 61
- Round size: Seed $1.3M–$8.4M; Series A $6M–$50M; Series B $16M–$226M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
- Xias Bio — Xias Bio is a biotechnology startup specializing in the production of recombinant proteins, offering formulators advanced soluble, active ingredients with improved attributes such as enhanced gel and film formation, as well as antioxidant properties. The company creates non-immunogenic natural motifs to produce a better delivery platform offunctionalities for research, beauty, and healthcare.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
RMGP Biopharma Investment Fund is an investment Fund
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Life Science
- Stage:Seed, Series B
- Geography: Israel
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Pi Therapeutics — Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and hasoperated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
- Skip Therapeutics — Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.
Show more...Investment focus
- Industry: Software, E-Commerce, Health Care
- Stage:Seed, Angel, Series A
- Geography: Italy, United States, United Kingdom
Investor stats
- Total investments: 105
- Round size: Seed $329k–$5.1M; Angel $219k–$987k; Series A $3M–$14M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Cato AI — Search, analyze and bid on Italian public tenders with AI, automating the manual work for bid offices and sales teams.
- AUDIOGEN — Generate your sounds with AI. Create an infinite world of sounds - sound effects, samples, and music, instantly. Get Started Free.
- Alomana — Autonomous systems for enterprise
PeakBridge is a highly networked, global impact VC that funds and connects the people, technology and processes that will shape the future of food. We invest in visionary pioneers, from early stage to Series A-B, with scalable, protectable climate and health-focused technologies. At their core: a deep commitment to disrupting our food system whiledriving positive impact. Our team is spread across seven countries and includes pioneers of FoodTech investment and decades of deep Agri-Food operational and financial experience. Together, we create exceptional value for bold FoodTech entrepreneurs and investors. A member of the Edmond de Rothschild Private Equity partnership, PeakBridge is also the only venture capital firm that is an official partner of the world’s largest Agri-Food innovation initiative, EIT Food.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Series A, Seed, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 56
- Round size: Seed $501k–$11M; Series A $4.5M–$17M; Series B $11M–$50M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — raised $106M in 2022
Portfolio highlights
- Myota — Precision prebiotic products developed by gut microbiome scientists. Clinically proven to improve your mental and physical health, and patented.
- Ilant Health — We offer a comprehensive solution that take the stress and stigma out of obesity treatment. We increase access, improve quality, and drive reduction in total cost of care.
- KÄÄPÄ Biotech — Medicinal mushrooms, biotechnology, mycology, forestry, agroforestry, and food production.
Agriline is the investment vehicle owned by a trust of which Trendlines' controlling shareholder Vincent Tchenguiz.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Israel
Investor stats
- Total investments: 15
- Round size: Seed $1.3M–$7.5M; Series A $5M–$17M; Venture - Series Unknown $2.2M–$16M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Vessi Medical — Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
- SetBone Medical — SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis.
Neo Ventures is a venture capital investment platform focused on deep tech, funds and high-growth startup portfolio.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 18
- Round size: Seed $500k–$2.9M; Series A $2.3M–$24M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Bulbi — Bulbi is a child development platform designed to help parents discover online and face-to-face educational activities for their children.
- Convex — All gas, no breakages. Convex is the reactive backend platform that keeps up with you and your agents.
- Extend Robotics — Extend Human Capabilities Beyond Physical Presence
South Israel Bridging Fund is a venture capital firm.
Show more...Investment focus
- Industry: Software, Biotechnology, Energy
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Israel, Cyprus, United States
Investor stats
- Total investments: 19
- Round size: Series A $1.5M–$34M; Series B $7M–$8.1M; Venture - Series Unknown $750k–$2M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $200M in 2020
Portfolio highlights
- Gadfin — Gadfin design and develops long-range Urgent-delivery systems of the future, which is no less than a game-changer for the Medical and Time-critical deliveries market. Its system brings together traditional flight knowledge, unmanned and autonomy technology, thus redefining delivery capabilities in terms of flight radius, safety, reliability, andautomation, that is going to disrupt the world.
- Stargo — AI powered routing, pricing and payment solutions for the freight industry
- Electriq Global — Electriq is a hydrogen carrier that acts like coffee powder for a coffee machine - simplifying storage, transport, and use of hydrogen in off-grid applications and long-term storage.
Israel Biotech Fund – Building the future of Israeli BiotechIsrael Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies.Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs at or near clinical stages.Ourpartners include two top-tier international pharmaceuticals companies, institutional investors, family offices and high net worth individuals.Our key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance.We provide our portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: Israel, United States
Investor stats
- Total investments: 15
- Round size: Series A $9M–$25M; Series B $17M–$30M; Series C $19M–$45M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — raised $65M in 2019
Portfolio highlights
- Ukko — Our mission is to improve the lives of the millions that suffer from food allergies and gluten-related disorders
- Vensica Medical — Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.
- Nectin Therapeutics — NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics. Discover breakthrough protein expression technologies that power safer, more effective treatments.
The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Hardware
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 4
- Round size: Seed $500k–$1M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- LapSpace — LapSpace Medical was founded in 2011. It operates within the framework of the Misgav Venture Accelerator, part of The Trendines Group. The LapSpace team combines strong business and medical experience and knowledge.
- Sqwik - powered by Geev.Me.Tech LTD — Sqwik is a new way to create, join & follow fun activities, with new friends, within 3 hours.
- Digma Medical — Digma Medical | DiaGone - safe, one-time, 30 minute, minimaly-invasive, GI procedure for Restoring Glycemic Control for T2DM & NASH patients | No Implant
EIT Food is a European Knowledge and Innovation Community (KIC), which was set up to transform our food ecosystem. By connecting consumers with businesses, start-ups, researchers and students from around Europe, EIT Food supports innovative and economically sustainable initiatives which improve our health, our access to quality food, and our environment
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Grant, Non-Equity Assistance, Seed
- Geography: United Kingdom, Israel, Germany
Investor stats
- Total investments: 128
- Round size: Seed $226k–$9.7M; Grant $23k–$531k; Non-Equity Assistance $1.2k–$32k
- Lead/follow: 68% lead, 32% follow
Portfolio highlights
- Hooked Foods — Hooked Foods is working on a plant-based tuna substitute. By serving delicious plant-based seafood for everyone to enjoy, the company is leading the transition to a healthier seafood ecosystem. The company was established in 2019 and is headquartered in Sweden.
- Perfat Technologies — Perfect fats for better foods.
- Roslin Technologies — Roslin Tech is on a mission to improve protein production through disruptive technologies. Our core capability is in animal stem cells; we have developed the world’s perpetually self-renewing, pluripotent stem cells for animals (iPS cells) which will accelerate the development of cultivated meat for the consumer market.
Biotechnology Investor funding in Israel at a glance
Stats across 653 deals from 745 investors.
Access all 745 investors in Israel Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Israel investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 745 investors investing in Israel Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!